Physician profile
Devin Patel
NPI 1932542578
$7,546.96
in general payments reported to CMS, 2019-2025
25 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,892 · 2020: $204 · 2021: $420 · 2022: $406 · 2023: $673 · 2024: $453 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,624.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $4,471.28 | 2019-2020 | |
| Boston Scientific Corporation | $347.12 | 2019-2024 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $326.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $295.66 | 2020-2025 | Farxiga, Wainua |
| Amgen INC. | $251.99 | 2022-2025 | Repatha, Repatha |
| Pfizer INC. | $212.86 | 2021-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.63 | 2020-2025 | Lifevest |
| Abbott Laboratories | $185.93 | 2019 | |
| Merck Sharp & Dohme LLC | $158.44 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $145.10 | 2021-2023 | Camzyos |
| Bolton Medical INC | $128.49 | 2025 | Thoraflex Hybrid |
| Medtronic, INC. | $110.05 | 2021 | |
| Heartflow, INC. | $105.32 | 2024 | |
| Cardiovascular Systems INC. | $101.24 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.03 | 2022-2025 | Jardiance |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $69.52 | 2022-2023 | Kengreal, Cleviprex |
| Janssen Pharmaceuticals, INC | $67.79 | 2021-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $65.08 | 2023-2024 | |
| Terumo Medical Corporation | $43.29 | 2023 | Metacross Otw, Azur Cx Detachable, Glidewire |
| Scpharmaceuticals INC. | $37.80 | 2023-2025 | |
| Kestra Medical Technology Services, INC. | $37.00 | 2024-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $30.23 | 2023-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $27.02 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $17.86 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $15.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.